Document:

EX-10.11

 Exhibit 10.11 
 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

 AGREEMENT 
 Effective as of May 30, 2006, THE REGENTS OF THE UNIVERSITY OF COLORADO,
a body corporate, having its principal office at 201 Regent Hall, Regent Drive, Boulder, CO 80309 (“University”) and GLOBEIMMUNE, INC., a Delaware corporation, having its principal
office at 1450 Infinite Drive, Louisville CO 80027 (“GlobeImmune”), agree as follows: 
 1. GlobeImmune (as successor in
interest to Ceres Pharmaceuticals, Ltd.) and University (acting through University Technology Corporation) are parties to the Intellectual Property License Agreement dated September 18, 1997 (“License Agreement”), pursuant to
which GlobeImmune licensed certain patents and technology from University. 
 2.       The License
Agreement was amended March 18, 1998, June 1, 2001 and October 16, 2003 (the “Amendments”). 

3.       The parties desire to restate the License Agreement, as amended, for ease of reference. 

4.       Attached to this Agreement is a restated version of the License Agreement incorporating all of the terms
and conditions modified by the Amendments (the “Restated Agreement”). 
 5.      
GlobeImmune and University acknowledge and agree that: 
 (a) The purpose of this Agreement and the Restated
Agreement is to provide ease of reference when reviewing the License Agreement as amended by the Amendments. 
 (b) This
Agreement and the Restated Agreement do not in any way affect or modify any of GlobeImmune’s or University’s obligations under the License Agreement as amended by the Amendments. 
 6.       In the event of any conflict between the terms of the License Agreement as amended by the Amendments and the Restated Agreement, the License Agreement as
amended by the Amendments shall govern. 
 IN WITNESS WHEREOF, GlobeImmune
and University have executed this Agreement by their duly authorized representatives as of the date first set forth above. 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

  

									
	GLOBEIMMUNE, INC.	 		 	THE REGENTS OF THE UNIVERSITY OF
COLORADO
					
	By:	 	/s/ Timothy C. Rodell, M.D.	 		 	By:	 	/s/ David N. Allen
	Name:	 	Timothy C. Rodell, M.D.	 		 	Name:	 	David N. Allen
	Title:	 	President and Chief Executive Officer	 		 	Title:	 	Assoc. VP

  
 2 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 UNIVERSITY TECHNOLOGY CORPORATION 

RESTATED INTELLECTUAL PROPERTY LICENSE 
 AGREEMENT 
 INTELLECTUAL PROPERTY LICENSE AGREEMENT, dated September 18, 1997,
between University Technology Corporation, a Colorado not-for-profit corporation, as Licensor, and Ceres Pharmaceuticals, Ltd., a Colorado corporation, as Licensee.

 RECITALS 
  

	A.	Licensor is the owner of certain intellectual property, which is specified and defined below as “Licensed Intellectual Property.” 

 

	B.	Licensee is a newly-formed company, whose founders made the inventions (the “Inventions”) that are the subject matter of the Licensed Intellectual Property.

  

	C.	Licensee desires to conduct further research and development with respect to the Inventions and to commercialize the Inventions. 

 

	D.	Licensee desires to acquire from Licensor, and Licensor desires to grant to Licensee, all rights in, to and under the Licensed Intellectual Property that may be
necessary or desirable to enable Licensee and/or its Sublicensees to conduct further research and development with respect to the Inventions, to commercialize the Inventions, to manufacture and sell Licensed Products, and to license other Persons to
use Licensed Processes for commercial purposes, in all cases subject to the terms and conditions of this Agreement. 

  

	E.	The parties desire for the Licensee to remit, and for the Licensor to receive, Royalties from the sale of Licensed Products to other Persons and the use of Licensed
Processes by other Persons, and to receive [*] Royalties, subject to the terms and conditions of this Agreement. 

TERMS OF AGREEMENT 

NOW, THEREFORE, in consideration of the premises and the mutual covenants and conditions set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, it is agreed: 

  
 1 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 ARTICLE 1. 

Definitions 
 The
following definitions and defined terms apply throughout this Agreement, including the Recitals. A variant of a defined term (e.g., “your” is a variant of “you’) has an appropriate correlative definition. 

 

	1.1	“Advance” shall have the meaning set forth in Section 5.2. 

 

	1.2	“Affiliate” means, when used in reference to a specified Person, any Person that directly or indirectly controls or is controlled by or is under common
control with the specified Person. Without limiting the foregoing, “Affiliate” also means, when used in reference to Licensee, any Person who shall acquire or who enters into a contract to acquire (whether by merger, consolidation,
transfer or any other lawful transaction) all or substantially all the assets or outstanding common stock of Licensee. For purposes of this Agreement, the University of Colorado is an Affiliate of Licensor. 

 

	1.3	“Agreement” means this Intellectual Property License Agreement and any amended or modified version hereof. 

 

	1.4	The “commercial sale” of a Licensed Product refers to the sale of such Licensed Product for commercial purposes, after all necessary approvals of the
United States Food and Drug Administration have been obtained. Such term excludes any sales for research purposes or for use in clinical testing or clinical trials. 

 

	1.5	The “commercial use” of a Licensed Process refers to the use of such Licensed Process for commercial purposes, after all necessary approvals of the
United States Food and Drug Administration have been obtained. Such term excludes any use for research purposes or for purposes of conducting clinical testing or clinical trials. 

 

	1.6	The term “commercialize,” when used with reference to the Licensed Intellectual Property, Inventions, Licensed Products or Licensed Processes, shall
refer to and include all activities reasonably related to the commercial sale or other commercial exploitation of Licensed Products, or reasonably related to the commercial use or other commercial exploitation of Licensed Processes, including,
without limitation, the conducting or sponsoring of research and development activities with a view to the eventual development of Licensed Products that are suitable for commercial sale or other commercial exploitation and/or the eventual
development of Licensed Processes that are suitable for commercial sale or other commercial exploitation. 

  

	1.7	The phrase, “covered by the Licensed Intellectual Property” shall mean covered by a valid and unexpired claim of any Patent. A claim shall be presumed
valid unless and until it has been held invalid by the final judgment of a court of competent jurisdiction and all rights of appeal from such final judgment have been exhausted. 

  
 2 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

	1.8	“Founders” means the founders of Licensee: Drs. Donald Bellgrau, Richard C. Duke, and Alex Franzusoff. 

 

	1.9	“Future Founder-University Inventions” means inventions or discoveries created or developed by one or more of the Founders, acting solely in his or
their capacity as employees or faculty members of the University of Colorado, if and to the extent such inventions or discoveries would not infringe one or more claims of the Licensed Intellectual Property and regardless of whether other
individuals are also listed as inventors on the relevant invention disclosure or any subsequent patent application. 

  

	1.10	“Infringement” means any infringement of any Licensed Intellectual Property by a Third Person. 

 

	1.11	“Inventions” shall have the meaning set forth in Recital B above. 

 

	1.12	“Licensed Intellectual Property” shall mean (a) those patents and patent applications listed on Exhibit 1 attached hereto, and any
divisions, continuations, re-examinations or re-issues of, and any continuations-in-part
that are directed to subject matter specifically described in, such patents or patent applications and (b) any patent or patent application owned or controlled by Licensor to the extent it claims an Improvement. 

 

	1.13	“Licensed Process” shall mean any process or method that is covered by the Licensed Intellectual Property. 

 

	1.14	“Licensed Product” shall mean any product, system or thing that is covered by the Licensed Intellectual Property. 

 

	1.15	“Licensee” means Ceres Pharmaceuticals, Ltd., a Colorado corporation. 

 

	1.16	“Licensor” means University Technology Corporation, a Colorado
not-for-profit corporation. 

  

	1.17	“Licensor’s Equity Shares” shall have the meaning set forth in Sections 9.1 and 9.2. 

 

	1.18	“Net Revenues” shall mean, 

  

	 	(a)	[*] 

  

	 	(b)	[*] 

  

	1.19	“Notice of Infringement” shall have the meaning set forth in Section 8.2. 

 

	1.20	“Patent” means any issued patent, whether United States or foreign, that is one of the patents constituting the Licensed Intellectual Property.

  
 3 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

	1.21	“Patent Applications” means and includes the patent applications included in the Licensed Intellectual Property. 

 

	1.22	“PCT” means the Patent Cooperation Treaty of 1970, as amended. 

 

	1.23	“Person” means and includes each party to this Agreement and any other corporation, partnership, trust, natural person, governmental entity or agency
thereof, or other legal entity. 

  

	1.24	“Royalties” shall have the meaning set forth in Section 5.1. 

 

	1.25	“Sublicense” and “Sublicensee, shall have the meanings set forth in Section 3.1. 

 

	1.26	“Sublicense Fee, shall mean any payment (whether made in the form of cash or other property) received by Licensee from any Sublicensee upon or in connection
with the execution of any Sublicense or any option to obtain a Sublicense, if such payment is made under the terms of the Sublicense or option and is not contingent upon any sales of Licensed Products or Licensed Processes or upon any performance on
the part of Licensee. “Sublicense Fee” shall not in any event include any amount paid to Licensee by any Sublicensee or other Person, (a) as fair consideration for research and/or development services, (b) as an investment in or
loan to Licensee, or (c) as consideration for any other property, rights or services that have been or are expected to be furnished by Licensee to such Person. 

 

	1.27	“Third Person” shall mean any Person who is not a party to this Agreement and is not an Affiliate of a party to this Agreement.

  

	1.28	“Total Equity Investment” shall mean the aggregate dollar amount received by Licensee, calculated cumulatively from the date of Licensee’s
formation, in payment for the issuance of shares of Licensee’s common stock or in payment for the issuance of shares of any other equity security. 

  

	1.29	1.29 “Improvements” shall mean inventions or discoveries owned or controlled by the Licensor, if and to the extent such inventions or discoveries would
infringe one or more claims of the patents or patent applications listed on Exhibit 1. The parties hereto agree that inventions or discoveries arising from the collaborations listed in Exhibit 2 hereto shall be Improvements
under the terms of this Agreement. 

 ARTICLE 2. 

Grant of Rights 
  

	2.1	 Licensor hereby grants and agrees to grant to Licensee, upon the terms and conditions set forth in this Agreement, and subject to Sections 2.2 and 2.3,
the exclusive rights under the Licensed Intellectual Property to make, have made, use and sell Licensed Products 

  
 4 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
and Licensed Processes throughout the world and otherwise to exploit the Licensed Intellectual Property commercially throughout the world. Except as expressly provided to the contrary in Article
12, the license herein granted is irrevocable and nonterminable throughout the term of this Agreement. 
  

	2.2	Notwithstanding the exclusive rights granted in Section 2.1, Licensor reserves to itself, for the benefit of the University of Colorado, the nonexclusive right to
use Licensed Intellectual Property for academic and research purposes; provided, however, that such nonexclusive right may not be transferred or sublicensed to any Person other than the University of Colorado and may not in any event
be used outside the University of Colorado, or for commercial purposes, or for the commercial benefit of any Person other than Licensee. Notwithstanding the foregoing proviso, any Founder who becomes associated with any academic institution other
than the University of Colorado or who becomes associated with a not-for-profit organization or
not-for-profit corporation may continue to conduct research with respect to any Licensed Intellectual Property regardless of whether he is associated with the University
of Colorado at the time the research is conducted. 

  

	2.3	Notwithstanding the exclusive rights granted in Section 2.1, the license herein granted shall be subject to the preexisting rights of the United States Government
in any Licensed Intellectual Property. 

  

	2.4	Licensee shall deliver to Licensor no later than June 15, 2001, and thereafter on an annual basis before the ninetieth (90th) day following the close of
Licensee’s fiscal year, a business plan and progress report showing the funds, personnel, and time budgeted and planned for development and commercialization of the Licensed Intellectual Property and the progress achieved on such plans to date.

  

	2.5	Licensee shall deliver to Licensor no later than sixty (60) days after the end of each of the first three calendar quarters, summary financial statements and
balance sheets for the preceding quarter. Licensee shall deliver to Licensor no later than ninety (90) days after the close of its fiscal year, its summary year-end financial statement and balance sheet
for the preceding fiscal year (such quarterly and annual financial statements and balance sheets, the “Financial Statements”). Licensor shall only disclose the Financial Statements to those of its employees, representatives and agents
requiring knowledge. Licensor shall use its best efforts to protect and preserve the proprietary and confidential nature of the Financial Statements, and shall be responsible for any unauthorized disclosure of the Financial Statements by employees,
representatives and agents to whom the Financial Statements have been disclosed by Licensor. 

  

	2.6	 Except for its contractual reporting obligations to the University of Colorado requiring disclosure to those representatives of the University of
Colorado who have a “need to know” due to the economic interests granted in the proceeds of this Agreement, Licensor represents that it is under no obligation, pursuant to any policy, regulation, law or otherwise, to provide the Financial
Statements, either directly or indirectly, to any third 

  
 5 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
party. Licensor represents that any disclosure of the Financial Statements to representatives of the University of Colorado shall not trigger disclosures mandated by the Colorado Public Records
Act (C.R.S. §§ 24-72-201 et seq.) as the statute reads on the Effective Date. Licensor further covenants that should it be required to disclose, either
directly or indirectly, to any third party the Financial Statements, Section 2.5 shall immediately terminate and Licensee will have no further obligation to provide such information to Licensor or any third party, unless such disclosure is in
response to a subpoena issued by a court or other governmental agency of competent jurisdiction and Licensee has been provided written notice thereof and the opportunity to seek confidential treatment prior to such disclosure. 

ARTICLE 3. 

Sublicenses 
  

	3.1	Licensee may grant one or more sublicenses (“Sublicenses”) of any or all the rights granted to Licensee hereunder, to one or more other Persons
(“Sublicensees”), in each instance on such terms as Licensee, in its sole discretion, deems appropriate; provided, however, that: 

  

	 	(a)	no Sublicense shall have the purpose or the intent of allowing Licensee to avoid any of its obligations hereunder; 

 

	 	(b)	each Sublicense shall be expressly subject to all the terms and conditions of this Agreement; and 

 

	 	(c)	each Sublicensee shall agree to be bound by the terms and conditions of this Agreement to the extent the same apply to the rights sublicensed. 

 

	3.2	Each Sublicensee shall be provided with a copy of this Agreement, and Licensee shall send Licensor a copy of each sublicense immediately after it is executed.

  

	3.3	If any Sublicense Fee is paid in connection with any Sublicense, [*]. 

 ARTICLE 4. 
 Funding and Commercialization 

 

	4.1	Immediately upon the execution and delivery of this Agreement, Licensee shall use [*] to obtain funding or financing from any lawful sources (including, without
limitation, private investments, private grants, public and private research contracts, or governmental grants), at such times and in such amounts as will enable Licensee to make all required payments hereunder on a timely basis and to conduct
further research and development with respect to the Inventions. 

  
 6 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

	4.2	Licensee shall at all times exercise [*] to commercialize the Licensed Intellectual Property, whether directly, or through one or more Sublicensees, or in conjunction
with one or more other Persons. 

  

	4.3	Licensee shall be deemed to have satisfied its obligations under Sections 4.1 and 4.2 if it: 

 

	 	(a)	obtains [*] in funding or funding commitments from any of the sources described in Section 4.1 within eighteen months after the date hereof; and

  

	 	(b)	expends [*] on research and development during [*] after the date hereof. 

 The accomplishment of (a) and (b) above is to be construed as sufficient means, and not the exclusive means, of Licensee satisfying its obligations under Sections 4.1 and 4.2. 

ARTICLE 5. 

Royalties [*] 
  

	5.1	Licensee shall pay Licensor royalties (“Royalties”) equal to either of the following, as applicable: 

 

	 	(a)	[*] of all Net Revenues [*] with respect to Licensed Products or Licensed Processes; or 

 

	 	(b)	[*] of all Net Revenues [*] with respect to Licensed Products or Licensed Processes. 

Subject to the provisions of Section 5.2, Licensee shall begin paying Royalties each calendar quarter after it first receives any
Net Revenues. Each Royalty payment shall be made within [*] after the end of the calendar quarter during which the Licensee received the Net Revenues upon which Royalties are then being paid. 

 

	5.2	Licensee shall pay Licensor nonrefundable advances against Royalties (“Advances”), in the following amounts and at the following times:

  

	 	(a)	[*] 

  

	 	(b)	[Intentionally omitted per Amendment No. 2.] 

  

	 	(c)	[*]. 

  

	 	(d)	[*]. 

  

	 	(e)	[*]. 

  

	 	(f)	[*]. 

 Each Advance shall be
credited against (i.e., shall offset) future Royalties, until the full amount of such Advance has been credited (i.e., recouped) in full. 

  
 7 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

	5.3	Each Royalty payment shall be accompanied by a detailed statement showing the basis for the computation of the Royalties then being paid, including reasonably detailed
information regarding Net Revenues received (and allowable deductions therefrom) during the period for which Royalties are then being paid, as well as the type and number of Licensed Products sold (with the authority of Licensee or any Sublicensee)
and Licensed Processes used (with the authority of Licensee or any Sublicensee) during such period. [*]. 

  

	5.4	Licensee shall keep full, true and accurate books of account containing all particulars that may be necessary for the purpose of showing Net Revenues received and the
amounts of Royalties [*] payable. Such books of account shall be kept at Licensee’s principal place of business. Once each calendar year, during normal business hours and on five business days’ written notice, Licensor or its designee
shall be entitled to audit the books and records of Licensee in order to determine whether Licensee has made proper payments of Royalties, and for no other purpose. Any information concerning Licensee that the auditors may obtain in the course of
performing such audit will be maintained as secret and confidential, will not be disclosed to any other Persons, and will not be used for any purpose other than obtaining the payment in full of Royalties due. No claim for underpayment of Royalties
[*] shall be valid or shall be brought more than [*] after the end of the calendar quarter in which the alleged underpayment occurred; and any such claim that is not brought within such time shall be deemed waived and discharged.

  

	5.5	If any Licensed Product or Licensed Process is covered by more than one Patent, [*]. 

 

	5.6	Licensee shall pay Licensor a portion of any Sublicense Fee received by Licensee [*]: 

 

	 	(a)	[*]. 

  

	 	(b)	[*]. 

  

	 	(c)	[*]. 

 [*]. 

 

	5.7	Notwithstanding Section 5.6 or any other provision of this Agreement, [*]. 

 ARTICLE 6. 
 Patent Prosecution and Maintenance 

 

	6.1	Except as provided in Section 6.3: 

  

	 	(a)	Licensee shall diligently prosecute the Patent Applications in the United States and such other jurisdictions that Licensee in its sole discretion deems to be in the
Licensee’s best interests; 

  
 8 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

	 	(b)	Licensee shall maintain every Patent as active; and 

  

	 	(c)	Licensee shall pay when due all filing fees, maintenance fees, taxes, attorneys’ fees and other costs and expenses associated with the activities described in
Sections 6.1(a) and (b). 

  

	6.2	Licensee shall provide Licensor promptly with copies of all filings and communications relating to the Licensed Intellectual Property, including but not limited to
copies of all correspondence with the United States Patent Office or any foreign patent office. 

  

	6.3	Licensee may abandon any Patent or Patent Application by notifying Licensor of such abandonment in writing, not less than thirty days before any filing, fee payment, or
other official action is required to be taken with respect to the Patent or Patent Application to be abandoned. After any such notice of abandonment has been given: 

 

	 	(a)	Licensee shall have no further obligation to prosecute or maintain the Patent or Patent Application so abandoned; 

 

	 	(b)	Licensee shall have no further rights in, to or under the Patent or Patent Application so abandoned; and 

 

	 	(c)	Licensor may thereafter continue the Prosecution of the Patent or Patent Application so abandoned. 

ARTICLE 7. 

Rights Resulting from Future Research 
  

	7.1	The Founders intend, but are not obligated, to continue conducting research and development, as employees and faculty members of the University of Colorado, with
respect to the Inventions and related technology. 

  

	7.2	 University hereby grants to Licensee an exclusive option to obtain the exclusive, worldwide, commercial rights to any Future Founder-University
Inventions arising after the Effective Date (the “Future Inventions Option”), on terms and conditions to be negotiated by the parties following the exercise by Licensee of the Future Inventions Option. University shall disclose to Licensee
in reasonable written detail any such Future Founder-University Invention after the University’s Technology Transfer Office receives notification from the inventor(s) that such Future Founder-University Invention has been made, and Licensee
shall have ninety (90) days (the “Option Period”) following receipt of such invention disclosure to exercise the Future Inventions Option with respect to such Future Founder-University Invention by delivering to University written
notice indicating that Licensee desires to exercise the Future Inventions Option. Upon such notice, the parties shall negotiate in good faith for a period of up to sixty (60) days commercially reasonable terms and conditions for a license under
the intellectual property rights 

  
 9 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
relating to such Future Founder-University Invention; provided that, if Licensee is negotiating the terms of such license in good faith, but no agreement has been reached in a sixty (60) day
period, such period shall automatically extend for additional sixty (60) day periods so long as Licensee continues to negotiate in good faith during such subsequent periods. If Licensee exercises the Future Inventions Option, Licensee will
agree to [*] for the Future Founder-University Invention prior to and during the Option Period and appertaining license negotiation period; provided that, such [*] without the prior written consent of Licensee [*]. Licensee will [*]. If Licensee
exercises the Future Inventions Option [*]. In the event that Licensee exercises the Future Inventions Option, but no such license is executed during the negotiation period, Licensor agrees not to make an offer for a license to the Future
Founder-University Invention on more favorable terms to a third party for a period of [*] without first offering Licensor those more favorable terms. 
  

	7.3	[Intentionally omitted per Amendment No. 3] 

  

	7.4	Licensor shall not own or have (and nothing in this Agreement shall constitute a grant of) any rights in, to or under any patents, inventions, technology or other
intellectual property: 

  

	 	(a)	that may be created or developed at any time by Licensee, using its own facilities, for its own account and benefit; or 

 

	 	(b)	that may be created or developed at any time by Licensee, using its own facilities, under a contract with, or under a grant from, a Third Person.

  

	7.5	The rights of Licensee in and to any particular Future Founder-University Invention, as set forth in Section 7.2 and Section 7.3, are subject to any prior
rights that may exist in favor of any Third Person who has provided funds to the University of Colorado or to Licensor that were used in order to finance the development of such Future Founder-University Invention. 

 

	7.6	Licensee, at its sole discretion, may make embodiments of the Licensed Intellectual Property available to employees or faculty members of the University of Colorado
solely for internal research purposes pursuant to appropriate material transfer or other research-related agreements. Licensor acknowledges and agrees that (i) with respect to inventions or discoveries arising from activities conducted as
permitted by such agreements, regardless of when such material transfer agreements are executed, (a) any Improvements shall be treated as provided in this Agreement and (b) any other inventions or discoveries shall be subject to
Section 7.4(b); and (ii) it hereby approves of the form of materials transfer agreement attached hereto as Exhibit 3 and, by execution hereof, unconditionally agrees to become a party to, and does hereby join, such agreement and agrees to
perform all obligations required to be performed by it under the Material Transfer Agreement and to be bound by each and every provision contained therein as though the undersigned had executed each Material Transfer Agreement.

  
 10 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 ARTICLE 8. 

Infringement of Licensed Intellectual Property 
  

	8.1	Each party shall exercise reasonable diligence in identifying actual or potential Infringements. Subject to the specific procedures, terms and conditions set forth in
this Article 8, each party will cooperate with the other in investigating and/or terminating any Infringement or alleged Infringement, whether through legal action, negotiation or otherwise. Such cooperation shall include, without limitation: each
party directing its employees to testify and grant interviews upon the request of the other party; and each party producing all reasonably pertinent records, papers, information, samples, specimens and similar items upon the request of the other
party. Each party shall render such cooperation at its own cost and expense. 

  

	8.2	If either party obtains knowledge of facts that it reasonably believes give rise to a claim for Infringement, such party shall promptly notify the other party of such
facts in writing (“Notice of Infringement”). The party issuing any Notice of Infringement shall state in reasonable detail all facts known to it that form the basis of the Notice of Infringement. 

 

	8.3	Licensee shall have, for a period of 120 days from the date of a Notice of Infringement, the exclusive right to institute an action for Infringement against such third
party. If Licensee institutes such suit, it may join Licensor as a plaintiff and Licensor shall cooperate with Licensee, at Licensee’s expense, in the prosecution of such suit. Licensee shall bear the entire cost of such litigation. Any
recovery in excess of litigation costs and attorney fees shall be shared with Licensor as follows: 

  

	 	(a)	[*]; 

  

	 	(b)	[*]; 

  

	 	(c)	Except as provided in (iv) below, if there is no apportionment in the damages recovered, whether in a judgment or in a settlement or otherwise, then all damages
shall be considered damages for [*]; and 

  

	 	(d)	Licensee and Licensor agree to negotiate in good faith an appropriate compensation to Licensor for any non-cash settlement or non-cash cross-license. 

  

	8.4	 If Licensee fails to institute such action within such 120-day period (or by written notice declines to
institute such action), then Licensor may, but is not obligated to, institute suit, and at its option, join Licensee as a plaintiff. If Licensor decides to institute suit, it shall notify Licensee in writing. Licensee shall have fifteen
(15) days after receipt of such notice to notify Licensor that it agrees to join in the suit and the suit shall be brought in both their names. All litigation costs and fees shall be borne equally, and any recovery or settlement shall be shared
equally. Licensor and Licensee shall agree to the manner in which they shall exercise control over such suit. Either party, at its option, may be 

  
 11 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
represented by separate counsel of its own selection, the fees for which shall be paid by such party. Licensee’s failure to notify Licensor in writing within fifteen (15) days after the
date of Licensor’s notice, that it will join in the suit pursuant to the terms hereof, shall be deemed conclusively to be Licensee’s assignment to Licensor of all rights, causes of action, and damages resulting from any such alleged
Infringement. Licensor shall bear the entire cost of such litigation and shall be entitled to retain the entire amount of any recovery or settlement. 
  

	8.5	Should either Licensor or Licensee commence a suit under the provisions of this Article 8 and thereafter desire to abandon same, it shall give timely notice to the
other party who may, if it so desires, continue prosecution of such suit, provided, however, that the sharing of expenses, attorney fees and any recovery in such suit shall be as agreed upon between the parties.

  

	8.6	[Intentionally omitted per Amendment No. 2.] 

  

	8.7	If any Third Person commences a declaratory judgment action alleging invalidity or noninfringement of any Licensed Intellectual Property: 

 

	 	(a)	the party first receiving the summons and complaint in such action (whether by formal service or otherwise) shall immediately forward a copy to the other party;

  

	 	(b)	Licensor shall have the right, but not the obligation, to defend such action, at its sole cost and expense; 

 

	 	(c)	if Licensor fails to agree in writing to defend such declaratory judgment action at its sole cost and expense within ten calendar days after it receives (whether
through service of process, or under Section 8.7(a), or in any other manner) a copy of the summons and complaint in such action, Licensee shall have the right, but not the obligation, to defend such action; and 

 

	 	(d)	the commencement of such declaratory judgment action shall be treated the same as the issuance of a Notice of Infringement pursuant to Section 8.2, thereby
entitling Licensor and/or Licensee (subject to the other term and conditions of this Article 8) to take action in an attempt to terminate any alleged Infringements by the Person (i.e., the plaintiff) who commenced the declaratory judgment
action. 

  

	8.8	The parties expressly recognize the possibility that upon the issuance of any Notice of Infringement or upon the commencement of any declaratory judgment action
alleging invalidity or noninfringement of Licensed Intellectual Property, they may agree to a course of action other than as set forth above, upon mutually satisfactory terms and conditions. 

  
 12 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 ARTICLE 9. 

Licensor’s Equity 
  

	9.1	Promptly after the execution and delivery of this Agreement, Licensee shall issue to Licensor [*] shares of its common stock [*] (“Licensor’s Equity
Shares”). Licensor’s Equity Shares issued to Licensor pursuant to this Article 9 shall be in addition to any other shares issued to Licensor under any other license agreement between the parties. 

 

	9.2	[*] 

  

	9.3	Licensor represents that it is acquiring the Licensor’s Equity Shares for investment purposes only and not with a present view to the resale or distribution
thereof 

  

	9.4	Licensee has no present intent to register Licensor’s Equity Shares under the Securities Act of 1933 or under the securities laws of any state. Licensor’s
Equity Shares may not be sold, transferred or hypothecated in the absence of such registration, unless Licensee receives an opinion of counsel satisfactory to Licensee to the effect that the proposed sale, transfer or hypothecation may lawfully be
made. 

  

	9.5	If the Founders register their shares of the common stock of Licensee under the Securities Act of 1933, Licensee will use its best efforts to register the common stock
portion of Licensor’s Equity Shares at the same time and on the same terms and conditions as the Founders’ registration. If less than all the shares held by the Founders are registered on any particular occasion, Licensee will use its best
efforts to have the same proportion of the Licensor’s Equity Shares registered on that same occasion. 

  

	9.6	Licensor shall not sell or otherwise dispose of any Licensor’s Equity Shares to any Third Person unless Licensor first offers Licensee, in writing, the opportunity
to purchase such Licensor’s Equity Shares on the same terms and conditions as those on which it proposes to sell or otherwise dispose of such Licensor’s Equity Shares to such Third Person. Licensee shall have thirty days to accept or
reject, in writing, any offer made by Licensor pursuant to this Section 9.6. If Licensee does not issue a timely acceptance or rejection of any such offer, the offer shall be deemed rejected, and Licensor shall be free to sell such
Licensor’s Equity Shares to such Third Person on the terms and conditions offered to Licensee, subject to any applicable provisions of this Agreement (including, without limitation, the provisions of this Article 9) and any applicable laws,
rules or regulations. Notwithstanding the above, Licensor may distribute Licensor’s Equity Shares pursuant to its agreement with University of Colorado to which it is bound and Licensee shall provide such certificate(s) in the names of such
recipients of such Shares specified by UTC as necessary for this purpose. Such distribution shall not be subject to Licensee’s right of first offer as set forth in this Section 9.6. 

ARTICLE 10. 
 Product Liability 
  

	10.1	 Licensee agrees to indemnify, defend and hold harmless Licensor, the University of Colorado, and their respective trustees, directors, officers,
employees and Affiliates (each an “Indemnitee”), from and against any claims and expenses, including reasonable 

  
 13 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
attorneys’ fees and other legal expenses, arising out of any death or injury to any Person or Persons caused or allegedly caused by Licensee, by any Licensed Product or by any Licensed
Process; provided, however, that no Indemnitee shall be indemnified under this Agreement for its own negligence or for the negligence of any other Indemnitee. 

 

	10.2	Licensee shall obtain product liability insurance on such terms and in such amounts as are reasonable and customary within its industry for companies similarly
situated. 

 ARTICLE 11. 
 Warranty Disclaimer 
 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT,
LICENSOR MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR VALIDITY OF ANY PATENTS OR PATENT CLAIMS INCLUDED
WITHIN THE LICENSED INTELLECTUAL PROPERTY. 
 ARTICLE 12. 

Term and Termination 
  

	12.1	The term of this Agreement and the grant of rights made herein shall extend until the expiration of the term (including all extensions thereof) of the last patent
included within the Licensed Intellectual Property, unless this Agreement is sooner terminated by either party in accordance with the provisions hereof. 

  

	12.2	Licensor may terminate this Agreement if Licensee fails to make any payment of Royalties when due hereunder [*], but only if such failure is not cured within thirty
days after Licensor gives Licensee notice of such nonpayment in writing, stating Licensor’s election to terminate this Agreement for nonpayment. In the event of such uncured nonpayment, termination shall take effect at the conclusion of the thirty-day period, without the necessity of further action or notice. In the event of a bona fide dispute regarding whether Licensee has made all payments required hereunder or whether any payment made by Licensee
has been incorrect in amount, Licensor may not terminate this Agreement for nonpayment of the disputed amount unless the dispute is finally resolved in Licensor’s favor and Licensee fails to pay the amount of the deficiency within thirty days
after such final resolution. 

  

	12.3	 Either party may terminate this Agreement if the other party is in default of a material provision hereof, but only if such default continues and
remains uncured for a period of ninety days after the aggrieved party gives the defaulting party notice in writing, specifying the default in detail and stating the aggrieved party’s election to terminate this Agreement by reason of such
default; provided, however, that any default described in 

  
 14 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
Section 12.2 shall be governed exclusively by such Section. In the event of such uncured default, termination shall take effect at the conclusion of the
ninety-day period, without the necessity of further action or notice. 
  

	12.4	Licensee may terminate its rights and obligations hereunder separately with respect to any patent included within the Licensed Intellectual Property, with or without
cause, on sixty days’ written notice to Licensor. 

  

	12.5	Upon and after the termination of this Agreement, regardless of the reason for termination, Licensee and its Sublicensees shall nonetheless have the right to sell their
entire existing inventories of Licensed Products and shall also have the right to complete any Licensed Processes then ongoing insofar as may be necessary in order to avoid undue hardship. 

 

	12.6	The termination or expiration of this Agreement shall not affect the rights or obligations of either party accruing prior to such termination or expiration, including
without limitation the obligation to pay Royalties with respect to Licensed Products sold or Licensed Processes used after the date of termination pursuant to Section 12.5. 

ARTICLE 13. 
 Assignment 
  

	13.1	Licensor may assign and transfer to any Person, on such terms and conditions as Licensor in its sole discretion deems appropriate, its right to receive Royalties [*]
hereunder. Licensor may also assign and transfer this Agreement in its entirety to the University of Colorado. 

  

	13.2	Licensee may assign and transfer to any Affiliate of Licensee, on such terms and conditions as Licensee in its sole discretion deems appropriate, any or all of its
rights in, to and under Licensed Intellectual Property and/or any other rights of Licensee arising under this Agreement. 

  

	13.3	Except as provided above in this Article 13, neither this Agreement nor any right or obligation hereunder shall be assignable by either party without the prior written
consent of the other party, which consent shall not be unreasonably withheld, and any purported or attempted assignment without such consent shall be void. Any permitted assignee shall be bound by all the terms and conditions of this Agreement to
the same extent as the assignor. No assignment shall relieve any party of any obligation under this Agreement, whether accruing before or after the assignment. 

  
 15 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 ARTICLE 14. 

Compliance with Laws, Export Controls and University Regulations 

 

	14.1	Each party will comply with all laws, regulations, ordinances, agency pronouncements and other legal requirements that may be applicable to the activities conducted by
such party pursuant to or as contemplated by this Agreement. 

  

	14.2	Without limiting Section 14.1, the parties acknowledge that certain bylaws, rules and regulations of the University of Colorado, and certain laws of the State of
Colorado, apply to the conduct of commercial enterprises by current and former faculty members and employees of the University of Colorado. Each party represents to the other that to the best of its knowledge and belief, none of the research,
developmental or commercial activities contemplated in this Agreement to be conducted by the Founders as employees or agents of Licensee, or by Licensee, would violate any such bylaws, rules, regulations or laws. 

 

	14.3	The parties acknowledge that they are subject to the laws and regulations of the United States that govern and restrict (in specified circumstances) the export of
technical data, computer software, laboratory prototypes and other commodities, including without limitation the Arms Export Control Act, as amended, and the Export Administration Act of 1979. Nothing in this Agreement shall be interpreted so as to
require or permit Licensor or Licensee to violate any such export laws or regulations. 

  

	14.4	Licensee specifically acknowledges that it may be required to obtain a permit or license from the United States Government or an agency thereof prior to exporting any
materials or data. Licensee agrees to obtain all such required permits and licenses prior to exporting any such materials or data. 

 ARTICLE 15. 
 Notices, Other Communications and Payments 

 

	15.1	Unless otherwise provided in this Agreement, any notice or other communication permitted or required hereunder shall be deemed to have been duly given or made if in
writing and delivered by any of the following methods to the party to whom it is directed: (a) hand delivery; (b) first class or certified mail; or (c) facsimile. Such notice or communication shall be deemed given or made upon its
receipt, by an employee possessing the appropriate level of authority, at the office of the party to whom it is directed. The addresses and facsimile numbers of the parties are: 

  
 16 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Licensor: 

University Technology Corporation 

3101 Iris Avenue, Suite 250 
 Boulder, CO 80301 
 Facsimile: 303
440-5875 
 Attention:     Jerry Donahue

                    
 President and CEO 
 Licensee: 

Ceres Pharmaceuticals, Ltd. 
 1899 Gaylord Street 
 Denver, CO 80206 

Facsimile: 303 333-8423 

Attention:     Richard Duke, Ph.D. 

                    
 President 
 Either party may change its address, facsimile or contact person for purposes of this Section by sending notice
of its change of address to the other party in compliance with the notice provisions of this Section. 
  

	15.2	Payments made by either party to the other hereunder shall be made in the manner provided in the preceding Section with respect to notices and other communications.

 ARTICLE 16. 
 Miscellaneous 
  

	16.1	Patent marking. Licensee shall mark each Licensed Product sold in the United States, or the packaging thereof, with the applicable United States Patent
number(s), in accordance with the patent laws of the United States. Licensee shall mark each Licensed Product sold outside the United States with the applicable patent number(s), in accordance with the laws applicable to each such sale.

  

	16.2	Nonuse of names. Nothing herein shall constitute the grant of a license or permission by either party to use such party’s name, or the name of any employee
or Affiliate of such party, for any advertising or promotional purposes; provided, however, that either party may state, publicly or privately, that the Licensed Intellectual Property is owned by the Licensor and has been licensed by
Licensee from Licensor. 

  
 17 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

	16.3	Relationship of parties. The parties to this Agreement are independent and unrelated. Neither party is the agent, partner or
co-venturer of the other, and neither party shall hold itself out, or knowingly permit itself to be perceived as, an agent, partner or co-venturer of the other.

  

	16.4	Founders’ rights. Nothing in this Agreement shall limit or otherwise affect the rights of the Founders, as faculty members of the University of Colorado and
as the inventors of the Inventions, to receive a portion of the revenues derived from the Inventions or Licensed Intellectual Property; and none of such rights of the Founders shall limit or otherwise affect the payment of Royalties [*] to Licensor
hereunder; provided, however, that the Founders shall not have any right to receive any portion of the profits, if any, that may be realized by Licensor upon the sale or other disposition of Licensor’s Equity Shares.

  

	16.5	Further assurances. If and to the extent it is within Licensor’s ability to do so, Licensor shall grant and convey to Licensee, for no additional
consideration, any further rights and permissions held or controlled by Licensor that Licensee may require in order to more fully enjoy the rights granted in this Agreement and otherwise to make, use and sell Licensed Products and Licensed
Processes. 

  

	16.6	Negative covenant. Licensor shall not enter into any contract or undertaking that conflicts with the rights herein granted to Licensee or that, upon the
happening of any reasonably foreseeable future event, shall conflict with the rights herein granted to Licensee. 

  

	16.7	Benefit. This Agreement shall be binding upon, and shall inure to the benefit of, the parties and their permitted successors and assigns.

  

	16.8	Headings. All headings in this Agreement are for convenience of reference only and shall be ignored for purposes of construing and interpreting this Agreement.

  

	16.9	Severability. If any part of this Agreement shall be adjudged by any court or other tribunal of competent jurisdiction to be invalid, such judgment shall not
affect or nullify the remainder of this Agreement, which shall be given effect in accordance with the manifest intent hereof 

  

	16.10	Force majeure. Except for the failure to make payments when due, neither party shall be liable to the other party by reason of any failure in performance or
delay in the performance of this Agreement if the failure or delay arises out of acts of God, illness, acts of the other party, acts of governmental authority, strikes, delays in transportation, war or any cause beyond the reasonable control of the
party so affected. If any such event delays performance, the time allowed for such performance shall be appropriately extended. 

  
 18 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

	16.11	Waiver. No failure on the part of either party to exercise, and no delay in exercising, any right, power or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any right, power or privilege hereunder preclude further exercise of the same right or the exercise of any other right hereunder by either party. 

 

	16.12	Manufacturing. All Licensed Products leased or sold within the United States shall be manufactured substantially within the United States, so long as such
requirement exists under Public Law 96-517, as amended by Public Law 98-620. 

 

	16.13	Entire agreement. This Agreement constitutes the entire agreement and understanding between the parties with respect to the subject matter hereof and supersedes
and cancels all prior agreements and negotiations between the parties relating thereto. The Recitals on the first page hereof are incorporated into, and are a part of, this Agreement. 

 

	16.14	Amendment. This Agreement may not be modified, amended, or supplemented except in a written instrument signed by both parties. 

 

	16.15	Governing law. This Agreement and the construction and enforcement of the provisions hereof shall be governed by the internal laws of the State of Colorado,
without regard to the conflict of laws provisions thereof; provided, however, that as to any issue that cannot be resolved without determining the validity, scope or enforceability of the rights accruing under any of the Patents, such
issue shall be resolved and determined in accordance with the laws of the country that issued the patent in question. 

  

	16.16	Material Transfer Agreement. A true and complete copy of the Material Transfer Agreement (“MTA”) with University of Colorado Health Sciences Center
(“UCHSC”) is attached hereto as Exhibit 3. Licensee shall provide copies of any revisions or modifications of such MTA and any new material transfer agreements or research agreements with UCHSC or University of Colorado within
ten (10) days of the execution of such agreements. 

 IN WITNESS WHEREOF, the parties have executed this Agreement as
of the date first written above. 
  

									
	 UNIVERSITY TECHNOLOGY CORPORATION
	 		 	
					
		 	/s/ Michael G. Gabridge	 		 		 	
				
	By:	 	 Michael G. Gabridge, Ph.D.

President and CEO
	 		 	Date: 10/2//97

  
 19 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

									
	CERES PHARMACEUTICALS, LTD.	 		 	
					
		 	/s/ Richard C. Duke	 		 		 	
				
	by:	 	 Richard C. Duke, Ph.D.

President
	 		 	Date: 9/18/97

  
 20 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 EXHIBIT 1 
 Licensed Intellectual Property 
 Patents 

 

									
	 Country
	  	Patent No.	  	Issue Date	  	Title	 
	 [*
	  		  		  	 	]	  

 Patent Applications 
  

					
	 Country
	  	Serial No.	  	File Date
	 [*]
	  		  	

  

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 EXHIBIT 2 
 Collaborations 
 [*] 

  

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 EXHIBIT 3 
 Form of MTA for USHSC Researchers 
 MATERIALS TRANSFER AGREEMENT

 THIS MATERIALS TRANSFER AGREEMENT (the
“Agreement”) is entered into the [            ] day of [            ],
200            by and between GLOBEIMMUNE, INC. (“GlobeImmune”), with offices at 12635 E. Montview Blvd., Suite 138,
Aurora, Colorado 80010, and the Regents of the University of Colorado on behalf of the University of Colorado Health Sciences Center (“Recipient”). 
 WHEREAS, GlobeImmune owns certain biological materials or has rights to transfer such biological materials to Recipient; and 

WHEREAS, Recipient desires to receive the biological materials to conduct certain research and investigations and
GlobeImmune desires to permit Recipient to conduct such research and investigation under the terms and conditions as set forth below. 

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties agree as follows: 
 1. Provision of Materials Identified in Exhibit A. GlobeImmune shall supply the
biological materials identified on Exhibit A (hereinafter “Material”) to Recipient solely for the non-commercial research purposes identified on Exhibit B
(“Research Project”). The Material includes any additional progeny, mutants or derivatives which cannot be made but for the use of such Material. The Material may also include Confidential Information (as defined in
Section 3.1 below) related to the production of the Material that is disclosed to Recipient in connection with Recipient’s use of the Material, such Confidential Information to be treated as provided in Section 3.1
below. GlobeImmune will deliver a reasonable quantity of Material (to be determined by GlobeImmune) to Recipient within a reasonable period of time after execution of this Agreement by both parties. That Material will be provided to
[            ] (“Principal Investigator”). GlobeImmune shall retain all right or interest in and to the Material. 

2. Use of Material. The Material will be used only by Principal Investigator or by individuals working under Principal Investigator’s direct
supervision for the Research Project and will not be transferred, distributed or released to any other person outside Principal Investigator’s immediate research group without GlobeImmune’s prior written consent. The Material is only made
available to Recipient for investigational use in laboratory animals or in in vitro experiments and will not be used in humans or in contact with any cells or other materials to be infused into humans. Recipient shall use the
Material in compliance with all applicable laws and regulations, including those relating to the handling of containment of the Materials. Recipient shall use the Material solely for academic research purposes and not for any commercial purpose. 

 3. Confidential Information, Research Information and Publications. 

3.1 No Disclosure. Recipient agrees that it shall not disclose the Confidential Information (as defined below) to any third party
other than the Principal Investigator or individuals working under Principal Investigator’s direct supervision and shall use the Confidential Information solely for the 

  
 1 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
purposes specified in Section 2 above. For purposes of this Agreement, “Confidential Information” means the Material, any information related to the Material and any
other information disclosed by GlobeImmune to Recipient and identified as confidential or proprietary. Notwithstanding the foregoing, the confidentiality obligations specified in this Section shall not apply to: (a) information that is
at the time of disclosure or subsequently becomes, part of the public domain through no fault of Recipient; (b) information in Recipient’s possession before receipt from GlobeImmune; (c) information that is received from a third party
without breach of confidentiality obligations; (d) information that is independently developed by an employee or consultant of Recipient who has not had the particular information disclosed to him/her; or (e) information which Recipient is
required by law to disclose, provided that Recipient gives GlobeImmune reasonable prior notice of the intent to disclose and cooperates with GlobeImmune to seek a protective order or other restrictions. Recipient’s obligations under this
Section 3.1 shall survive any termination or expiration of this Agreement. 
 3.2 Material Tracking.
Recipient will store all Material in a secure location under direct control of Recipient, separate from other publicly available banks or libraries of materials, even when stored within the laboratory of the Principal Investigator. Recipient
will track each distribution and use of Material to individuals working under Principal Investigator’s direct supervision. Recipient will keep a written record that includes the individual’s name, date of distribution and purpose.

 3.3 Publications. Recipient shall have the right to publish the results of the Research Project so long as such
publication does not violate Section 3.1. Recipient agrees to submit to GlobeImmune for its review and comment, a copy of any proposed publication, abstract or other disclosure resulting from such activities, such as by oral
presentation, manuscript or abstract, at least forty-five (45) days prior to any such presentation or publication. If no response from GlobeImmune is received by Recipient within thirty (30) days of the date received by GlobeImmune, it
will be conclusively presumed that the publication may proceed without delay. If GlobeImmune feels that the conclusions are not supported by the data, then the parties shall make a good faith attempt to resolve such issues, and at GlobeImmune’s
request Recipient shall delay publication for an additional thirty (30) days to allow such discussion. Recipient shall comply with GlobeImmune’s request to delete any references to GlobeImmune’s Confidential Information contained in
the proposed publication or disclosure. At GlobeImmune’s request, Recipient will, for a reasonable period up to ninety (90) days from initial delivery to GlobeImmune, delay revealing any patentable subject matter in the disclosure in order
to permit the filing of patent applications. 
 4. Inventions. Except as otherwise agreed by the parties pursuant to their Intellectual
Property License Agreement dated September 18, 1997 (as amended), any inventions, innovations or ideas resulting from Recipient’s use of Material, including improvements to or derivatives of the Material (“Inventions”),
shall belong solely to GlobeImmune. GlobeImmune may, at its election and expense, pursue and obtain patent protection for any inventions that may incorporate use of the Material or the Research Information. Recipient is granted no other right or
license to the Material under any patent rights now or hereafter held by GlobeImmune, nor is any implied hereby. Recipient shall notify GlobeImmune in a timely manner of any Invention conceived, discovered or reduced to practice in connection with
this Agreement and shall exert best efforts, in cooperation with GlobeImmune and at GlobeImmune’s expense, in the filing and subsequent prosecution of any patent applications based upon any such Inventions. 

5. Warranties. RECIPIENT ACKNOWLEDGES AND AGREES THAT
THE MATERIAL IS EXPERIMENTAL IN NATURE AND, THEREFORE, IS SUPPLIED TO
RECIPIENT “AS IS,” WITH NO WARRANTIES OF ANY KIND,

  
 2 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY
OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY WARRANTY
OF NON-INFRINGEMENT OR TITLE. GLOBEIMMUNE SHALL NOT BE
LIABLE FOR ANY USE OF THE MATERIAL BY RECIPIENT OR FOR ANY
LOSS, CLAIM, DAMAGE OR LIABILITY OF ANY KIND OR NATURE WHICH MAY
ARISE FROM OR IN CONNECTION WITH THIS AGREEMENT OR FROM THE USE,
HANDLING OR STORAGE OF THE MATERIAL. 
 6. Term and
Termination. This Agreement shall be effective upon the date first above written and shall continue for one (1) year after Recipient’s receipt of the Material. This Agreement may be extended beyond such initial term upon the mutual
written agreement of the parties, which will not be unreasonably withheld. Either party may terminate this Agreement at any time upon thirty (30) days written notice to the other party. Within ten (10) days after the expiration or
termination of this Agreement, Recipient shall return all Material and any copies of the Confidential Information and Research Information in Recipient’s possession or within its control to GlobeImmune or shall deliver written notice certifying
that all Material, Confidential Information and Research Information has been destroyed. The obligations of each party under Sections 3, 4 and 5 shall survive the expiration or termination of this Agreement. 

 

	7.	Miscellaneous. 

 7.1
Entire Agreement. The parties agree that this Agreement, including the exhibits, contains the entire understanding and agreement between the parties with respect to the subject matter hereof and supersedes all previous communications, proposals,
representations and agreements, whether oral or written, relating to the subject matter hereof. This Agreement may only be amended or modified by a writing signed by both parties. The parties hereby represent and warrant that the officials signing
this Agreement have the power to do so on behalf of the parties. 
 7.2 Successor and Assigns. Neither party shall assign
this Agreement or any rights hereunder without the prior written consent of the other party; provided, however, that no consent shall be required for any assignment in connection with the sale of all or substantially all of the business of
the party to which this agreement relates. Subject to the foregoing, this Agreement shall be binding upon and inure the benefit of the parties hereto and their respective successor and assigns. 

7.3 Governing Law. This Agreement shall be governed by the laws of the State of Colorado, without regard to it conflicts of law
principles. Each section shall be independent and separable from all other sections, and the invalidity of a section shall not affect the enforceability of any of the other sections. 

IN WITNESS WHEREOF, this Agreement has been executed by the duly
authorized representatives of the parties. 
  

			
	THE REGENTS OF THE UNIVERSITY OF
COLORADO
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  
 3 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
			
	GLOBEIMMUNE, INC.
		
	By:	 	 
	Name:	 	
	Title:	 	 

  
 4 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 EXHIBIT A 

DESCRIPTION OF MATERIAL 

  
 1 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 EXHIBIT B 

RESEARCH PROJECT 

  
 1.EX-10.11.1

 Exhibit 10.11.1 
 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 
 Execution Version 
 AMENDMENT (1) 
 To 

AGREEMENT AND RESTATED INTELLECTUAL PROPERTY
LICENSE AGREEMENT 
 This Amendment to Agreement and Restated Intellectual Property License
Agreement (the “Amendment”), effective as of May 5, 2009 (the “Amendment Effective Date”) by and among GLOBEIMMUNE, INC., a corporation organized under the laws of
Delaware, having its principal office at 1450 Infinite Drive, Louisville, CO 80027 (“GlobeImmune”), THE REGENTS OF THE UNIVERSITY OF
COLORADO, a body corporate, having its principal office at 1800 Grant Street, 8th Floor, Denver, CO 80203 (“University”), and the UNIVERSITY LICENSE
EQUITY HOLDINGS, INC., a Colorado corporation and successor to the University Technology Corporation, having its principal office at 4740 Walnut Street, Suite 100, Campus Box 588, Boulder Colorado
80309 (“ULEHI”). 
 RECITALS 
 WHEREAS, GlobeImmune and University (acting through ULEHI) are parties to a certain Agreement, effective as of May 30, 2006 (the “Agreement”), and a certain Restated Intellectual
Property License Agreement, effective as of May 30, 2006 (the “Restated Agreement”); 
 WHEREAS,
University, ULEHI, and GlobeImmune desire to revise and amend the Agreement and the Restated Agreement; and 
 WHEREAS,
capitalized terms used herein but not defined herein shall have the definitions set forth in the Restated Agreement. 

AGREEMENT 

NOW, THEREFORE, GlobeImmune, University, and ULEHI agree as follows: 

 

	 	1.	The Agreement. 

 (a)
Section 5 of the Agreement shall be deleted and replaced in its entirety with the following: 
 5.
University represents and warrants that the License Agreement, as amended, including without limitation the Licensed Intellectual Property set forth in Section 1.12 and Exhibit 1 of the Restated Agreement, was validly assigned by the University
License Equity Holdings, Inc., a Colorado corporation (“ULEHI”), the successor to the University Technology Corporation, to The Regents Of The University Of Colorado. 

  
 1 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 (b) Section 6 of the Agreement shall be deleted and replaced in its entirety with
the following: 
 6. In the event of any conflict between the terms of the License Agreement as amended by the
Amendments and the Restated Agreement as amended, the terms of the Restated Agreement as amended shall govern. 
  

	 	2.	The Restated Agreement. 

 (a)
Section 1.15 of the Restated Agreement shall be deleted and replaced in its entirety with the following: 
  

	 	1.15	“Licensee” means GlobeImmune, Inc. 

 (b) Section 1.16 of the Restated Agreement shall be deleted and replaced in its entirety with the following: 
  

	 	1.16	“Licensor” means The Regents Of The University of Colorado; however, with regard to Article 9 and Section 16.4 (Licensor’s Equity) only,
Licensor shall mean University License Equity Holdings, Inc. (“ULEHI”), a Colorado non-profit corporation and the successor to the University Technology Corporation, and with regard to Article 10
(Product Liability) only, Licensor shall include both The Regents of the University of Colorado and the University License Equity Holdings, Inc. 

 (c) A new Section 2.7 shall be added to the Restated Agreement as follows: 
  

	 	2.7	 Each of Licensor and ULEHI represents and warrants to Licensee that (a) this Agreement and the Licensed Intellectual Property set forth in
Section 1.12 and Exhibit 1 were validly assigned by ULEHI (successor to the University Technology Corporation) to The Regents Of The University Of Colorado; (b) The Regents Of The University Of Colorado owns the Licensed Intellectual
Property set forth in Section 1.12 and Exhibit 1; (c) The Regents Of The University Of Colorado has the right to grant the rights and licenses granted to Licensee hereunder; (d) subject to Section 2.3 above, neither Licensor nor
ULEHI has granted, and neither Licensor nor any of its successors will grant during the term of this Agreement, any 

  
 2 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

	 	
right, license, or interest in, to, or under the Licensed Intellectual Property that would conflict or interfere with the rights granted to Licensee hereunder; (e) Licensee has had
continuous rights in the Licensed Intellectual Property pursuant to the terms of this Agreement since September 18, 1997 up to the date of the Amendment to Agreement and Restated Intellectual Property License Agreement, dated May 5, 2009;
(f) ULEHI is the successor in interest to University Technology Corporation, and all of University Technology Corporation’s rights and obligations with respect to this Agreement and the Licensed Intellectual Property; and (g) neither
Licensor nor ULEHI has transferred, and neither Licensor nor any of its successors will transfer during the term of this Agreement, any right, license, or interest in, to, or under the Licensed Intellectual Property that would conflict or interfere
with the rights granted to Licensee hereunder. 

 (d) Section 3.1 of the Restated Agreement shall be deleted
and replaced in its entirety with the following: 
  

	 	3.1	Licensee shall have the right to grant one or more sublicenses through multiple tiers of sublicensees (“Sublicenses”) under any or all of the rights granted,
and subject to any reservation of rights set forth in Sections 2.2 and 2.3, to Licensee hereunder, to one or more other Persons (“Sublicensees”), in each instance on such terms as Licensee, in its sole discretion, deems appropriate;
provided, however, that: 

 (a) No Sublicense shall have the purpose or the intent
of allowing Licensee to avoid any of its obligations hereunder; and 
 (b) [*]. 

(e) A new Section 3.4 shall be added to the Restated Agreement as follows: 

 

	 	3.4	 In the event of termination of this Agreement under Section 12.2 or Section 12.3, any Sublicensee of Licensee, from the effective date of
such termination, automatically shall become a direct licensee of Licensor under the terms of this Agreement with respect to the rights sublicensed to the Sublicensee by Licensee; provided that such Sublicensee (a) is not in breach of
its sublicense agreement with Licensee, (b) continues to perform under the terms of its sublicense agreement with Licensee, and [*]. In order to become a direct licensee in accordance with the foregoing sentence, such Sublicensee shall make any
payments required by Section 3.4(c) within [*] after 

  
 3 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

	 	
the effective date of such termination. For clarity, in the event of any failure of such Sublicensee to comply with the proviso in the first sentence of this Section 3.4 or upon such
Sublicensee’s election not to take a direct license, including without limitation by failing to [*] within the time period set forth in the second sentence of this Section 3.4, such Sublicensee shall not be deemed in breach of this
Agreement, such Sublicensee shall not have become a direct licensee of Licensor in accordance with the foregoing sentence, and this Agreement shall be terminated in accordance with its terms with respect to such Sublicensee as of the effective date
of such termination. 

 (f) A new Section 3.5 shall be added to the Restated Agreement as follows:

  

	 	3.5	In the event that Licensor provides any notice of Licensor’s election to terminate this Agreement under Section 12.2 or Section 12.3, Licensor shall
contemporaneously provide a copy of any such notice to any Sublicensee of Licensee that has obtained, in a Sublicense, exclusive rights under all or a portion of the rights granted to Licensee in this Agreement, at the address set forth in the
applicable notice provision of such Sublicense. 

 (g) Section 15.1 of the Restated Agreement shall be
updated so that the addresses and facsimile numbers of the parties for provision of notice shall be deleted and replaced with the following: 
 Licensor: 
 License Administrator, CU Case #IR 392H

 Office of Technology Transfer 

University of Colorado, 588 SYS 
 4740 Walnut Street 
 Boulder, CO 80309 

Facsimile. (303) 735-3831 

Licensee: 
 GlobeImmune, Inc. 
 1450 Infinite Drive 

Louisville, Colorado 80027 U.S.A. 

Attention: Chief Executive Officer 

Facsimile: (303) 625-2810 

  
 4 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

(h)            Exhibit 1 of the Restated Agreement shall be deleted in
its entirety and replaced with the Exhibit 1 set forth in Appendix A attached hereto. 

(i)            Exhibit 3 of the Restated Agreement shall be deleted in
its entirety and replaced with the Materials Transfer Agreement set forth in Appendix B attached hereto. As of the Amendment Effective Date, the parties shall use such updated version of the Materials Transfer Agreement. 

3.        Except as expressly modified by this Amendment, all terms and conditions of the
Agreement and the Restated Agreement shall continue in full force and effect. 

4.        In the event of any conflict between the terms of the Agreement or the Restated
Agreement and this Amendment, the terms of this Amendment shall govern. 

5.        This Amendment may be executed in counterparts, each of which shall be deemed an
original, but both of which together shall constitute one and the same instrument. 
 [Signature Page Follows] 

  
 5 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 IN WITNESS WHEREOF,
GlobeImmune, University, and ULEHI have executed this Amendment by their duly authorized representatives as of the Amendment Effective Date. 
  

									
	GLOBEIMMUNE, INC.	 		 	THE REGENTS OF THE UNIVERSITY OF
COLORADO
					
	By:	 	/s/ Timothy C. Rodell, M.D.	 		 	By:	 	/s/ David N. Allen, Ph.D.
	Name:	 	Timothy C. Rodell, M.D.	 		 	Name:	 	David N. Allen, Ph.D.
	Title:	 	President and CEO	 		 	Title:	 	Associate Vice President
				
		 		 		 	UNIVERSITY LICENSE EQUITY HOLDINGS, INC.
					
		 		 		 	By:	 	/s/ R.C. Mercure, Jr.
		 		 		 	Name:	 	R.C. Mercure, Jr.
		 		 		 	Title:	 	Chairman

 Signature Page to Amendment to Agreement 

and 
 Restated
Intellectual Property License Agreement 

  

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Appendix A 

  

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 EXHIBIT 1 
 Licensed Intellectual Property 
  

											
	 Patents and Patent Applications

	 Country
	 	 Application

No.
	 	 Filing Date
	 	 Patent No.
	 	 Issue Date
	 	 Title

	 [*]
	 		 		 		 		 	
		 		 		 		 		 	
		 		 		 		 		 	
		 		 		 		 		 	
		 		 		 		 		 	
		 		 		 		 		 	
		 		 		 		 		 	
		 		 		 		 		 	

  

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Additional Patents and Patent Applications 

[*] 

  

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Appendix B 

  

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 EXHIBIT 3 
 Form of MTA for USHSC Researchers 
 MATERIALS TRANSFER AGREEMENT

 THIS MATERIALS TRANSFER AGREEMENT (the
“Agreement”) is entered into the [            ] day of [            ],
200            by and between GLOBEIMMUNE, INC. (“GlobeImmune”), with offices at 12635 E. Montview Blvd., Suite 138,
Aurora, Colorado 80010, and the Regents of the University of Colorado on behalf of the University of Colorado Health Sciences Center (“Recipient”). 
 WHEREAS, GlobeImmune owns certain biological materials or has rights to transfer such biological materials to Recipient; and 

WHEREAS, Recipient desires to receive the biological materials to conduct certain research and investigations and
GlobeImmune desires to permit Recipient to conduct such research and investigation under the terms and conditions as set forth below. 

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties agree as follows: 
 1.            Provision of
Materials Identified in Exhibit A.    GlobeImmune shall supply the biological materials identified on Exhibit A (hereinafter “Material”) to Recipient solely for the non-commercial research purposes identified on Exhibit B (“Research Project”). The Material includes any additional progeny, mutants or derivatives which cannot be made but for
the use of such Material. The Material may also include Confidential Information (as defined in Section 3.1 below) related to the production of the Material that is disclosed to Recipient in connection with Recipient’s use of the
Material, such Confidential Information to be treated as provided in Section 3.1 below. GlobeImmune will deliver a reasonable quantity of Material (to be determined by GlobeImmune) to Recipient within a reasonable period of time after
execution of this Agreement by both parties. That Material will be provided to [            ] (“Principal Investigator”). GlobeImmune shall retain all right or
interest in and to the Material. 
 2.            Use of
Material.    The Material will be used only by Principal Investigator or by individuals working under Principal Investigator’s direct supervision for the Research Project and will not be transferred, distributed or
released to any other person outside Principal Investigator’s immediate research group without GlobeImmune’s prior written consent. The Material is only made available to Recipient for investigational use in laboratory animals or in in
vitro experiments and will not be used in humans or in contact with any cells or other materials to be infused into humans. Recipient shall use the Material in compliance with all applicable laws and regulations, including those relating to the
handling of containment of the Materials. Recipient shall use the Material solely for academic research purposes and not for any commercial purpose. 
 3.            Confidential Information, Research Information and Publications. 

3.1            No Disclosure.    Recipient agrees
that it shall not disclose the Confidential Information (as defined below) to any third party other than the Principal Investigator or individuals working under Principal Investigator’s direct supervision and shall use the Confidential
Information solely for the purposes specified in Section 2 above. For purposes of this Agreement, “Confidential Information”  

  
 1 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
means the Material, any information related to the Material and any other information disclosed by GlobeImmune to Recipient and identified as confidential or proprietary. Notwithstanding the
foregoing, the confidentiality obligations specified in this Section shall not apply to: (a) information that is at the time of disclosure or subsequently becomes, part of the public domain through no fault of Recipient;
(b) information in Recipient’s possession before receipt from GlobeImmune; (c) information that is received from a third party without breach of confidentiality obligations; (d) information that is independently developed by an
employee or consultant of Recipient who has not had the particular information disclosed to him/her; or (e) information which Recipient is required by law to disclose, provided that Recipient gives GlobeImmune reasonable prior notice of
the intent to disclose and cooperates with GlobeImmune to seek a protective order or other restrictions. Recipient’s obligations under this Section 3.1 shall survive any termination or expiration of this Agreement. 

3.2            Material Tracking.    Recipient
will store all Material in a secure location under direct control of Recipient, separate from other publicly available banks or libraries of materials, even when stored within the laboratory of the Principal Investigator. Recipient will track each
distribution and use of Material to individuals working under Principal Investigator’s direct supervision. Recipient will keep a written record that includes the individual’s name, date of distribution and purpose. 

3.3            Publications.    Recipient shall
have the right to publish the results of the Research Project so long as such publication does not violate Section 3.1. Recipient agrees to submit to GlobeImmune for its review and comment, a copy of any proposed publication, abstract or
other disclosure resulting from such activities, such as by oral presentation, manuscript or abstract, at least forty-five (45) days prior to any such presentation or publication. If no response from GlobeImmune is received by Recipient within
thirty (30) days of the date received by GlobeImmune, it will be conclusively presumed that the publication may proceed without delay. If GlobeImmune feels that the conclusions are not supported by the data, then the parties shall make a good
faith attempt to resolve such issues, and at GlobeImmune’s request Recipient shall delay publication for an additional thirty (30) days to allow such discussion. Recipient shall comply with GlobeImmune’s request to delete any
references to GlobeImmune’s Confidential Information contained in the proposed publication or disclosure. At GlobeImmune’s request, Recipient will, for a reasonable period up to ninety (90) days from initial delivery to GlobeImmune,
delay revealing any patentable subject matter in the disclosure in order to permit the filing of patent applications. 

4.            Inventions.    Except as otherwise agreed by the
parties pursuant to their Intellectual Property License Agreement dated September 18, 1997 (as amended), any inventions, innovations or ideas resulting from Recipient’s use of Material, including improvements to or derivatives of the
Material (“Inventions”), shall belong solely to GlobeImmune. GlobeImmune may, at its election and expense, pursue and obtain patent protection for any inventions that may incorporate use of the Material or the Research Information.
Recipient is granted no other right or license to the Material under any patent rights now or hereafter held by GlobeImmune, nor is any implied hereby. Recipient shall notify GlobeImmune in a timely manner of any Invention conceived, discovered or
reduced to practice in connection with this Agreement and shall exert best efforts, in cooperation with GlobeImmune and at GlobeImmune’s expense, in the filing and subsequent prosecution of any patent applications based upon any such
Inventions. 

5.            Warranties.    RECIPIENT
ACKNOWLEDGES AND AGREES THAT THE MATERIAL IS EXPERIMENTAL IN NATURE AND,
THEREFORE, IS SUPPLIED TO RECIPIENT “AS IS,” WITH NO WARRANTIES OF
ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY WARRANTY OF
NON-INFRINGEMENT OR TITLE. GLOBEIMMUNE SHALL NOT BE LIABLE
FOR ANY USE OF THE MATERIAL BY RECIPIENT OR FOR ANY LOSS,
CLAIM, DAMAGE OR LIABILITY OF ANY KIND OR NATURE WHICH MAY ARISE
FROM OR IN CONNECTION WITH THIS AGREEMENT OR FROM THE USE, HANDLING
OR STORAGE OF THE MATERIAL. 

  
 2 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 6.            Term and
Termination.    This Agreement shall be effective upon the date first above written and shall continue for one (1) year after Recipient’s receipt of the Material. This Agreement may be extended beyond such initial
term upon the mutual written agreement of the parties, which will not be unreasonably withheld. Either party may terminate this Agreement at any time upon thirty (30) days written notice to the other party. Within ten (10) days after the
expiration or termination of this Agreement, Recipient shall return all Material and any copies of the Confidential Information and Research Information in Recipient’s possession or within its control to GlobeImmune or shall deliver written
notice certifying that all Material, Confidential Information and Research Information has been destroyed. The obligations of each party under Sections 3, 4 and 5 shall survive the expiration or termination of this Agreement. 

7.            Miscellaneous. 

7.1            Entire Agreement.    The parties
agree that this Agreement, including the exhibits, contains the entire understanding and agreement between the parties with respect to the subject matter hereof and supersedes all previous communications, proposals, representations and agreements,
whether oral or written, relating to the subject matter hereof. This Agreement may only be amended or modified by a writing signed by both parties. The parties hereby represent and warrant that the officials signing this Agreement have the power to
do so on behalf of the parties. 
 7.2            Successor and
Assigns.    Neither party shall assign this Agreement or any rights hereunder without the prior written consent of the other party; provided, however, that no consent shall be required for any assignment in connection
with the sale of all or substantially all of the business of the party to which this agreement relates. Subject to the foregoing, this Agreement shall be binding upon and inure the benefit of the parties hereto and their respective successor and
assigns. 
 7.3            Governing
Law.    This Agreement shall be governed by the laws of the State of Colorado, without regard to it conflicts of law principles. Each section shall be independent and separable from all other sections, and the invalidity of a
section shall not affect the enforceability of any of the other sections. 

  
 3 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 IN WITNESS WHEREOF,
this Agreement has been executed by the duly authorized representatives of the parties. 
  

			
	THE REGENTS OF THE UNIVERSITY OF
COLORADO
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  

			
	GLOBEIMMUNE, INC.
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  

			
	READ AND UNDERSTOOD BY PRINCIPAL INVESTIGATOR:
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  
 4 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 EXHIBIT A 

DESCRIPTION OF MATERIAL 

  
 1 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 EXHIBIT B 

RESEARCH PROJECT 

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]